
Yuan Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/824423/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The CXCL8-CXCR1/2 pathways in cancer. Cytokine and Growth Factor Reviews, 2016, 31, 61-71.	7.2	471
2	Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. Journal of Hematology and Oncology, 2014, 7, 87.	17.0	196
3	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respiratory Medicine,the, 2021, 9, 1154-1164.	10.7	107
4	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 45-53.	10.7	105
5	Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Scientific Reports, 2015, 5, 10338.	3.3	96
6	Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the IncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. Oncogene, 2019, 38, 1225-1238.	5.9	89
7	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. Clinical Cancer Research, 2021, 27, 1296-1304.	7.0	79
8	Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS ONE, 2015, 10, e0131689.	2.5	75
9	Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. Oncotarget, 2016, 7, 7842-7855.	1.8	72
10	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Translational Lung Cancer Research, 2020, 9, 269-279.	2.8	64
11	Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype. Experimental Cell Research, 2020, 391, 111956.	2.6	61
12	Emerging roles of Nrf2 signal in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 14.	17.0	50
13	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+) Journal of Clinical Oncology, 2020, 38, 9519-9519.	1.6	50
14	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 83.	17.0	45
15	DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget, 2015, 6, 5877-5888.	1.8	40
16	Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget, 2015, 6, 31203-31215.	1.8	37
17	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. Cancer Letters, 2017, 403, 186-194.	7.2	27
18	A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study. , 2020, 8, e001314.		26

#	Article	IF	CITATIONS
19	Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling. Clinical Cancer Research, 2016, 22, 1531-1544.	7.0	24
20	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. Journal of Thoracic Oncology, 2021, 16, 827-839.	1.1	24
21	The roles of CC chemokines in response to radiation. Radiation Oncology, 2022, 17, 63.	2.7	21
22	The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. OncoTargets and Therapy, 2015, 8, 3575.	2.0	20
23	In Vitro Evaluation of the Inhibitory Potential of Pharmaceutical Excipients on Human Carboxylesterase 1A and 2. PLoS ONE, 2014, 9, e93819.	2.5	18
24	PDPN is a prognostic biomarker and correlated with immune infiltrating in gastric cancer. Medicine (United States), 2020, 99, e19957.	1.0	17
25	The Experiences of Communityâ€dwelling older adults during the COVIDâ€19 Lockdown in Wuhan: A qualitative study. Journal of Advanced Nursing, 2021, 77, 4805-4814.	3.3	17
26	Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Translational Lung Cancer Research, 2019, 8, 1016-1028.	2.8	16
27	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as firstâ€line treatment for Chinese patients with unresectable, metastatic, or recurrent nonâ€squamous non–smallâ€cell lung cancer: A multicenter, randomized, doubleâ€blinded, phase III trial. Cancer Communications, 2021, 41, 889-903.	9.2	16
28	Association of single nucleotide polymorphisms of ABCB1, OPRM1 and COMT with pain perception in cancer patients. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35, 752-758.	1.0	14
29	mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial–mesenchymal transition. Acta Pharmacologica Sinica, 2019, 40, 1085-1094.	6.1	14
30	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open-label, Randomized, Phase III Trial. Journal of Thoracic Oncology, 2018, 13, 1743-1749.	1.1	13
31	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. Lung Cancer, 2020, 146, 252-262.	2.0	12
32	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	2.8	12
33	Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer. OncoTargets and Therapy, 2015, 8, 2209.	2.0	11
34	Prior Study of Cross-Cultural Validation of McGill Quality-of-Life Questionnaire in Mainland Mandarin Chinese Patients With Cancer. American Journal of Hospice and Palliative Medicine, 2015, 32, 709-714.	1.4	10
35	lrinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis. BMC Cancer, 2018, 18, 808.	2.6	10
36	Comparison of the oncological, perioperative and functional outcomes of partial nephrectomy versus radical nephrectomy for clinical T1b renal cell carcinoma: A systematic review and meta-analysis of retrospective studies. Asian Journal of Urology, 2021, 8, 117-125.	1.2	10

#	Article	IF	CITATIONS
37	Characteristics of immune and inflammatory responses among different age groups of pediatric patients with COVID-19 in China. World Journal of Pediatrics, 2021, 17, 375-384.	1.8	10
38	The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin. Supportive Care in Cancer, 2018, 26, 2763-2767.	2.2	9
39	An online tool for predicting the prognosis of cancer patients with SARS-CoV-2 infection: a multi-center study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1247-1257.	2.5	8
40	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	2.8	7
41	SIX1 Predicts Poor Prognosis and Facilitates the Progression of Non-small Lung Cancer via Activating the Notch Signaling Pathway. Journal of Cancer, 2022, 13, 527-540.	2.5	7
42	miR-34C Disrupts the Stemness of Purified CD133 + Prostatic Cancer Stem Cells. Urology, 2016, 96, 177.e1-177.e9.	1.0	6
43	Impact of marital status on survival in patients with stage 1A NSCLC. Aging, 2022, 14, 770-779.	3.1	6
44	Discussion of Advance Care Planning on end of life decisions with lung cancer patients in Wuhan China: Attitude, Timing, and Future Directions. Internal Medicine Journal, 2020, , .	0.8	5
45	Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. Oncotarget, 2017, 8, 62330-62338.	1.8	5
46	Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring <i>MET exon 14</i> skipping alterations (<i>METex14</i>). Cancer Research, 2021, 81, CT158-CT158.	0.9	4
47	Knowledge, Practices, and Perceived Barriers in Cancer Pain Management at Oncology Units: A Cross-Sectional Survey of Medical Staff in China. Journal of Pain Research, 2022, Volume 15, 159-169.	2.0	4
48	Long noncoding RNA PVT1 regulates the proliferation and apoptosis of ARPE-19 cells <i>in vitro</i> via the miR-1301-3p/KLF7 axis. Cell Cycle, 2022, 21, 1590-1598.	2.6	4
49	Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inflammasome Activation, and Reversing Gut Microbiota Disorder. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	4.0	3
50	CYFRA 21-1 as an early predictor of first line chemotherapy response in advanced non small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2007, 6, P250-P253.	0.1	1
51	Preliminary results of gentamycin combined with sodium bicarbonate for prevention of irinotecan-induced diarrhea. Frontiers of Medicine in China, 2009, 3, 470-474.	0.1	1
52	Leinal polypeptide promotes NK cells to suppress PCa survival inÃ ⁻ Âį¼2vitro. Oncology Letters, 2018, 16, 425-430.	1.8	1
53	Lower lobe origin is related to unfavorable outcomes in patients with stage l–III lung cancer treated with radical chemoradiotherapy. Tumori, 2021, 107, 400-406.	1.1	1
54	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial Journal of Clinical Oncology, 2018, 36, 9077-9077.	1.6	1

#	Article	IF	CITATIONS
55	Treatment beyond progression with chemo-immunotherapy in an advanced esophageal squamous cell carcinoma patient: a case report. Translational Cancer Research, 2021, 10, 4973-4978.	1.0	1
56	Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer Journal of Clinical Oncology, 2022, 40, 9114-9114.	1.6	1
57	Detect T790M in cell free tumor DNA of Chinese advanced non-small cell lung cancer adenocarcinoma patients by different platforms and evaluate clinical outcomes of T790M positive patients with osimertinib monotherapy Journal of Clinical Oncology, 2017, 35, TPS9104-TPS9104.	1.6	0
58	A real-world study update: Efficacy and safety of anlotinib for advanced non-small cell lung cancer Journal of Clinical Oncology, 2022, 40, e21106-e21106.	1.6	0